Monthly Archives: May 2011

CBI Conference Highlights Innovative Programs on Patient Compliance

With compliance rates flagging, companies have to work harder than ever to demonstrate these programs have value and represent a good ROI Pharm Exec’s sister conference organization, CBI, sponsored its 10th annual Patient Adherence Forum in April to highlight current trends in industry compliance and adherence programs — where companies reach out to help an increasingly […]
Posted in Events, patient compliance | Tagged , , | Leave a comment

Florida Builds on Biotech Industry

While the biotechnology industry has weakened across the U.S., Florida has seen a 21 percent jump in the number of biotech companies since 2008 and a surge in investment, according to the University of Florida. Updated numbers from the Florida BioDatabase, maintained by the University of Florida’s Sid Martin Biotechnology Incubator. in Alachua, show 29 […]
Posted in Biotech | Tagged , , | Leave a comment

With Botanicals, No Patent, No Expiry, says Sanofi Exec

What if a new drug could be trademarked instead of patented, keeping generics companies at bay for the life of the trademark, i.e., forever? That was one of the ideas floated to reporters yesterday by Sanofi-Aventis’ Ray Jupp, VP of the fibrosis and wound repair therapeutic strategic unit, an early-stage research division created as part […]
Posted in R&D, Strategy | Tagged , , , , , | 3 Comments

Whither the Market Research Function?

PBIRG’s 50th anniversary meeting strikes a note for change—because the alternative is a drift toward organizational irrelevance It’s easy to be complacent about the harsh competitive challenges facing Big Pharma today. We all know what these challenges are, and the temptation is to address them in the abstract. As if all this complexity can be […]
Posted in Strategy | 1 Comment

Biosimilars Spend to Reach $2.5 Bln by 2015: IMS

Global spending on biosimilars is expected to reach between $2 and $2.5 billion by 2015, up from $311 million in 2010, according to an IMS forecast. Total spend on biologics is expected to climb as high as $200 billion. On a call with reporters yesterday, Murray Aitken, executive director of the IMS Institute for Healthcare […]
Posted in Agency Insight, Biotech, Emerging Markets, Europe, Strategy | Tagged , , | 2 Comments
  • Categories

  • Meta